Preclinical Research

BPC-157 Research: What Studies Show About Tissue Repair

Published: March 2026 • Educational content for research purposes only

---

Introduction to BPC-157

BPC-157, or Body Protection Compound-157, is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a naturally occurring protein found in gastric juice, discovered and extensively studied by Croatian researcher Predrag Sikiric and his team at the University of Zagreb School of Medicine. Since the early 1990s, this compound has been the subject of a substantial body of preclinical research, predominantly in rodent models, examining its effects on various tissue repair processes.

The sequence of BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) was originally isolated from human gastric juice. The rationale for its study stems from the observation that the stomach, despite being a highly acidic environment exposed to digestive enzymes, possesses extraordinary regenerative capacity. Researchers hypothesized that locally produced peptides might contribute to this protective and regenerative ability.

Proposed Mechanisms

The mechanisms by which BPC-157 is thought to exert its studied effects are multifactorial and remain under active investigation. The primary pathways implicated in the literature include:

• Angiogenesis modulation: Multiple studies in rodent models have reported enhanced formation of new blood vessels in healing tissues following BPC-157 administration. This effect appears to involve upregulation of VEGF (vascular endothelial growth factor) signaling pathways, which are critical to tissue vascularization during repair.
• Nitric oxide system interaction: Research has implicated the nitric oxide (NO) signaling system in many of BPC-157’s observed effects. The compound appears to modulate both eNOS and nNOS activity, with complex downstream effects on vascular tone, inflammation, and cytoprotection.
• Growth hormone receptor interaction: Some studies have proposed that BPC-157 may interact with growth hormone receptor pathways, potentially explaining effects observed in musculoskeletal tissue models.
• Anti-inflammatory signaling: Several rodent studies have reported reductions in inflammatory markers in various tissue injury models, suggesting possible modulation of pro-inflammatory cytokine production or activity.

Musculoskeletal Tissue Research

Perhaps the most extensively studied area of BPC-157 research involves musculoskeletal tissue — specifically tendons, ligaments, muscles, and bone. Sikiric’s group and affiliated researchers have published numerous studies examining the compound’s effects in standardized animal injury models.

In tendon transection models in rats, BPC-157 administration (via both systemic injection and local application) has been associated with accelerated functional recovery and histological evidence of improved tendon organization compared to controls. Studies examining Achilles tendon, quadriceps tendon, and rotator cuff injury models have reported broadly similar findings — suggesting a potentially general effect on connective tissue repair processes rather than tissue-specific action.

Muscle crush injury models have also shown potentially accelerated recovery in animals receiving BPC-157, with reported improvements in both functional endpoints (muscle force production) and histological markers of regeneration. Several studies have proposed that these effects may be mediated at least in part through the FAK-paxillin pathway, which is involved in cell migration and fibroblast activity during healing.

Gastrointestinal Research

Given its origin from gastric protein, BPC-157’s effects on gastrointestinal tissue have been a major research focus. Rodent studies have examined its effects in models of inflammatory bowel disease, esophageal injury, gastric ulceration, intestinal fistulas, and short bowel syndrome.

In colitis models (including TNBS and DSS-induced colitis), BPC-157 treatment has been associated with reduced macroscopic and microscopic damage scores, lower levels of inflammatory markers, and preservation of intestinal architecture. These findings have generated interest in BPC-157 as a potential candidate for inflammatory bowel disease research, though no human clinical trials have been completed in this indication to date.

Neurological and Systemic Effects

A smaller but growing body of research has examined BPC-157’s effects on neurological tissues and systemic organ protection. Studies in traumatic brain injury models, spinal cord injury models, and peripheral nerve injury models have reported potentially neuroprotective effects, with histological evidence of reduced neuronal loss in some experimental paradigms.

Systemic cytoprotective effects have also been reported, including potential protection against organ damage induced by NSAIDs, alcohol, and various toxins in animal models. These findings have been interpreted by some researchers as evidence of a broad cytoprotective mechanism, possibly related to the compound’s interactions with the NO system and stress response pathways.

Critical Assessment of the Literature

While the volume of BPC-157 preclinical research is substantial, several important limitations warrant consideration when interpreting this body of work. The vast majority of studies originate from a single research group (Sikiric’s laboratory in Zagreb), which limits independent validation. Animal model data, particularly in short-lived rodents, does not reliably predict human pharmacology or efficacy.

Additionally, the compound has not yet been the subject of published Phase II or Phase III clinical trials in humans for any tissue repair indication. One Phase II trial was reportedly initiated for inflammatory bowel disease, but results have not been formally published in peer-reviewed literature as of the writing of this article. The transition from robust animal model data to demonstrated human efficacy represents the critical unknown in BPC-157 research.

Conclusion

BPC-157 represents one of the most extensively studied synthetic peptides in the preclinical tissue repair literature. The breadth of its studied effects across multiple tissue types, combined with a plausible mechanistic framework involving angiogenesis, nitric oxide signaling, and anti-inflammatory pathways, makes it a scientifically interesting compound. However, the near-complete absence of published human clinical trial data means that the translation of these animal model findings to human biology remains unestablished. The compound warrants further rigorous investigation through well-designed clinical trials.